Targeted Axillary Dissection with ¹²⁵I Seed Placement Before Neoadjuvant Chemotherapy in a Danish Multicenter Cohort.

ABSTRACT:

Background

Targeted axillary dissection (TAD), with marking of the metastatic lymph node before neoadjuvant chemotherapy (NACT), is increasingly used for breast cancer axillary staging. In the case of axillary pathological complete response (ax-pCR), axillary lymph node clearance can be omitted. Several marking methods exist, most using re-marking before surgery. Feasibility, learning curve, and identification rate (IR) vary. Marking with ¹²⁵I seed before NACT makes re-marking at surgery redundant, possibly increasing feasibility and IR. Here, TAD with ¹²⁵I seed placed before NACT is evaluated in a Danish multicenter cohort.

Methods

Patients staged with ¹²⁵I TAD in Denmark between 1 January 2016 and 31 August 2021 were included. Patients were

SUBMITTER: Munck F 

PROVIDER: S-EPMC10250439 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature